Rock Vomer, DO
Sports Medicine · Wilmington, NCNPI 1740740448
Payments from drug & device makers
Across 56 payments — averaging $18.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$280
- Exact Sciences$120
- Baxter Healthcare$116
- AstraZeneca$78
- Novo Nordisk$78
- Otsuka America Pharmaceutical, Inc.$50
- plus $328 from 12 others
What the payments were for
- Food & beverage$1,050100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 17 | $280 |
| Exact Sciences | 7 | $120 |
| Baxter Healthcare | 4 | $116 |
| AstraZeneca | 5 | $78 |
| Novo Nordisk | 4 | $78 |
| Otsuka America Pharmaceutical, Inc. | 2 | $50 |
| Organon | 2 | $49 |
| Inspire Medical Systems, Inc. | 2 | $46 |
| Lilly USA, LLC | 3 | $46 |
| Axsome Therapeutics, Inc. | 2 | $34 |
| Radius Health, Inc. | 1 | $29 |
| Boehringer Ingelheim | 1 | $24 |
| Abbott | 1 | $22 |
| Astellas Pharma US Inc | 1 | $20 |
| Irhythm Technologies, Inc. | 1 | $17 |
| GSK | 1 | $15 |
| Amgen | 1 | $14 |
| Merck | 1 | $12 |
How this compares
$1,050 in reported general payments places this provider in the 45th percentile of 158 sports medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 12 | $241 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 11 | $239 |
| Omeprazole | 16 | $182 |
| Tizanidine Hcl | 21 | $177 |
| Rosuvastatin Calcium | 27 | $161 |
| Atorvastatin Calcium | 17 | $161 |
| Levothyroxine Sodium | 22 | $136 |
| Pantoprazole Sodium | 15 | $132 |
| Meloxicam | 19 | $126 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 19 | $110 |
| Amlodipine Besylate | 27 | $108 |
| Lisinopril | 13 | $89 |
| Gabapentin | 16 | $71 |
| Metformin Hcl | 13 | $14 |
Paid to pharmacies, not to this prescriber.
Other sports medicine in Wilmington
- Richard FerroWilmington$39K
- Shawn HockerWilmington$38K
- Scott DartWilmington$21K
- Dale BoydWilmington$15K
- John O'MalleyWilmington$15K
- Robert BoswellWilmington$7K
- William SuttonWilmington$3K
- Brian WatermanWinston Salem$466K
- Allston StubbsWinston Salem$184K
- Robert BoykinAsheville$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.